I don’t know how the market will view this decision, but I strongly support it. If seltorexant (MIN-202) becomes a commercial asset we will reap some reward with no more financial obligation. They can now focus capital solely on their top asset - roluperidone: “it has exercised its right to opt out of its agreement with Janssen Pharmaceutica NV (Janssen) for the future development of seltorexant (MIN-202).” “Minerva will now collect a royalty on worldwide sales of seltorexant in all indications in the mid-single digits, with no financial obligations to Janssen. ”
http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-exercises-right-opt-out-agreement-janssen